ICG-99mTc Nanotop混合示踪剂用于乳腺癌前哨淋巴结活检的首次人体可行性研究
平面淋巴显像与SPECT/CT术前检出率均为100%,SPECT/CT额外发现3枚平面显像未显示的同流域淋巴结。术中γ探测与近红外荧光探测计数呈强相关,未见不良反应。
要点
- ICG-99mTc Nanotop混合示踪剂可实现术前淋巴显像与术中实时荧光和γ探测的一体化。
- 术中γ计数与近红外荧光计数强相关,未见不良反应。
核心结论
- ICG-99mTc Nanotop混合示踪剂用于乳腺癌前哨淋巴结活检是可行、可靠且安全的。
研究设计与样本
- 术中采用光核探测器检测前哨淋巴结的γ信号与荧光信号,切除淋巴结行苏木精-伊红染色,术后1个月进行临床评估。
主要发现
- 平面淋巴显像和SPECT/CT在全部患者中至少识别1枚前哨淋巴结,术前检出率为100%。
- SPECT/CT发现3枚同流域额外淋巴结,而常规平面淋巴显像未显示(κ=0.747;P<0.005)。
- 全部30枚术前前哨淋巴结均在注射后16小时内定位并切除。
- γ探测计数与近红外荧光探测计数呈强相关(P<0.005,r=0.964)。
- 未观察到不良反应。
关键数值与推荐
- SPECT/CT较平面淋巴显像额外显示3枚淋巴结,一致性κ=0.747,P<0.005。
- 共30枚术前前哨淋巴结在注射后16小时内完成定位与切除。
- γ与近红外荧光计数相关系数r=0.964,P<0.005。
临床怎么用
- 该混合示踪剂可单次注射实现术前淋巴显像与术中实时荧光及γ探测,辅助乳腺癌前哨淋巴结活检。
- SPECT/CT有助于发现平面淋巴显像未显示的同流域淋巴结。
局限性
- 摘要未报告随机对照或长期随访结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The clinical introduction of a radioactive and fluorescent hybrid tracer allowed for preoperative lymphatic mapping and intraoperative real-time fluorescence tracing of the sentinel lymph node (SLN) by a single injection. The aim of this feasibility study is to evaluate the first-in-human use of the hybrid tracer by combining indocyanine green (ICG) and radiocolloid based on Nanotop compound (99mTc Nanotop) for SLN biopsy (SLNB) in breast cancer patients. METHODS: The day before surgery, ICG-99mTc Nanotop was injected periareolarly in breast cancer patients scheduled for SLNB. Planar lymphoscintigraphic (PL) and SPECT/CT images were then acquired. An intraoperative optonuclear probe was used to detect SLN gamma and fluorescent signals. The harvested SLNs were examined by hematoxylin-eosin staining, and patients were clinically evaluated 1 month after surgery. RESULTS: Twenty-one consecutive patients were enrolled. The PL and SPECT/CT techniques identified at least 1 SLN in all patients for a preoperative sentinel detection rate of 100%. SPECT/CT revealed 3 additional lymph nodes in the same nodal basin, which had not been visualized on conventional PL (κ = 0.747; P < 0.005). All 30 preoperative SLNs were localized and excised up to 16 hours after injection. The counts measured via gamma tracing showed a very strong correlation with those measured via near-infrared fluorescent tracing (P < 0.005, r = 0.964). No adverse reactions were observed. CONCLUSIONS: The SLNB technique used with the ICG-99mTc Nanotop tracer resulted to be feasible, reliable, and safe. This hybrid compound allowed us to obtain excellent performance in terms of both preoperative lymphatic mapping and intraoperative SLN detection in breast cancer patients.
引用
- Manca G, Garau LM, Mazzarri S, et al. Novel Experience in Hybrid Tracers: Clinical Evaluation of Feasibility and Efficacy in Using ICG-99mTc Nanotop for Sentinel Node Procedure in Breast Cancer Patients. Clin Nucl Med. 2021. PMID: 33323744. doi:10.1097/RLU.0000000000003478
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。